Form 10 Registration with the U.S. SEC

• Imricor has filed a Form 10 Registration Statement with the U.S. SEC
• Filing is a regulatory requirement due to the size of Imricor's shareholder base
• Does not indicate a U.S. public offering or stock exchange listing

Imricor Medical Systems, Inc. (ASX: IMR) has filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). The filing is a result of Imricor exceeding certain holder of record thresholds set forth in Section 12(g) of the U.S. Securities Exchange Act of 1934. Imricor's Chair and CEO, Steve Wedan, stated that the Form 10 filing requirement should not be interpreted as a U.S. public offering or a move in that direction, but rather a regulatory requirement due to the size of the company's shareholder base. Imricor remains committed to its ASX shareholders and will apply for a waiver from the ASX to avoid duplication of financial reporting obligations while complying with both ASX and SEC disclosure requirements. The Form 10 will become effective in the middle of May 2026, at which point Imricor will become a U.S. public reporting company and will be subject to periodic reporting requirements of the Exchange Act.